NovaBridge Biosciences announced its annual general meeting (AGM) will be held on September 8, 2026, in Shanghai. The company is advancing clinical-stage biopharmaceutical treatments, including givastomig for gastric cancer and VIS-101 for retinal diseases. These developments are significant as they target unmet medical needs with innovative therapies currently in Phase 2 trials. The AGM will also review the company's 2025 financial report and strategic plans moving forward.
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
Fabrinet is set to report strong Q3 2026 earnings with revenue forecasted at about $1.276 billion, a 41% increase year-over-year, driven by demand in Telecom and Data Center sectors. Earnings per share are expected to rise 45% to $3.81, reflecting ro...
Jernigan Capital, a REIT specializing in financing self-storage facilities, saw its stock rise over 11% to $24.00, reaching a new 52-week high. Analysts have a consensus "Moderate Buy" rating with an average 12-month price target of $27.50, suggestin...
CrowdStrike, a leading cybersecurity firm, has seen its stock price increase by 85% year-to-date, reaching a market cap over $220 billion. Investment firm Cowen & Co. reiterated a "Buy" rating and raised the price target to $235, citing strong financ...
Metallus is rated a buy due to strong Q2 demand, 12% year-over-year revenue growth, higher shipments, and improved net sales per ton. Aerospace and defense shipments surged, positioning the company for a potential re-rating if it reaches a $250 milli...
